Trial Profile

A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Elranatamab (Primary) ; Immunomodulators (Primary) ; Lenalidomide (Primary) ; Nirogacestat (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms MagnetisMM4
Sponsors Pfizer

12 Mar 2025 Planned End Date changed from 31 Jul 2027 to 23 Oct 2027.
12 Mar 2025 Planned primary completion date changed from 8 Nov 2025 to 31 Jan 2026.
18 Nov 2024 Planned End Date changed from 2 Jul 2027 to 31 Jul 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com